Sarepta Therapeutics, Inc. (SRPT) Income Statement

The revenue trajectory is highly erratic, with 2025Q1 showing 80.2% year-over-year growth, followed by a -34.3% contraction in 2026Q2. This volatility suggests dependence on discrete events such as inventory stocking or milestone payments rather than a steady commercial ramp. Investors should monitor whether the underlying product portfolio can deliver consistent sequential growth, as the 2026Q2 level is below the 2024Q4 figure of $658.4M, indicating a potential plateau or demand disruption.

The gross margin deterioration in 2025Q4, where COGS of $398.7M nearly matched revenue of $442.9M, suggests a major one-time charge or a shift toward lower-margin products. Even excluding that quarter, 2026Q2's 62.8% margin is well below the 80%+ levels seen in 2024, implying structural cost increases or pricing pressure. This may indicate that the company's manufacturing scale-up or supply chain costs are eroding profitability, warranting close scrutiny of COGS components.

The operating leverage is highly unstable, as SG&A has remained relatively flat (ranging $91.9M to $163.9M) while R&D fluctuates dramatically, reaching $773.4M in 2025Q1. This suggests that R&D investments are driving operating income volatility, with positive operating income only in quarters with lower R&D. The 2026Q1 operating margin of 49.0% appears unsustainable given the R&D intensity required for a biotech pipeline, implying that future profitability depends on disciplined R&D allocation.

The cost structure is dominated by R&D, which has ranged from $91.3M to $773.4M, reflecting clinical trial timing and potential milestone payments. COGS also shows extreme variability, with 2025Q4's $398.7M likely including inventory write-offs or supply chain disruptions. SG&A has been relatively stable, indicating management's control over commercial expenses, but the combined volatility in R&D and COGS makes cost forecasting difficult and may signal inefficiencies in production or trial management.

This quarter represents a strategic pivot, likely tied to a major clinical program or acquisition-related expense, as R&D spending more than tripled from the prior quarter's $200.4M. The lasting impact is a reset in profitability expectations, as subsequent quarters have not returned to the 2024 margin levels. This inflection suggests that the company is prioritizing pipeline advancement over near-term earnings, which may be necessary for long-term value but introduces significant financial risk if those programs fail.